Accession of tumor heterogeneity by multiplex transcriptome profiling of single circulating tumor cells

Clinical Chemistry

Volumn 62, Issue 11, 2016, Pages 1504-1515

  Gorges, Tobias M ^a   Kuske, Andra ^a   Röck, Katharina ^a   Mauermann, Oliver ^a   Müller, Volkmar ^a   Peine, Sven ^a   Verpoort, Karl ^b   Novosadova, Vendula ^c   Kubista, Mikael ^c,d   Riethdorf, Sabine ^a   Pantel, Klaus ^a  

^a UNIVERSITY MEDICAL CENTER HAMBURG EPPENDORF   (Germany)

^b Practice for Medical Oncology   (Germany)

^c INSTITUTE OF MATHEMATICS   (Czech Republic)

^d TATAA Biocenter   (Sweden)

Author keywords

[No Author keywords available]

Indexed keywords

ANDROGEN RECEPTOR; ANDROGEN RECEPTOR V7; CADHERIN; CADHERIN 1; CADHERIN 2; CD24 ANTIGEN; CXCL2 CHEMOKINE; CXCL9 CHEMOKINE; CYTOKERATIN 19; EPIDERMAL GROWTH FACTOR RECEPTOR 2; EPITHELIAL CELL ADHESION MOLECULE; EPITHELIAL MEMBRANE PROTEIN 2; ESTROGEN RECEPTOR ALPHA; HERMES ANTIGEN; INTERLEUKIN 15; INTERLEUKIN 1BETA; INTERLEUKIN 8; MACROPHAGE INFLAMMATORY PROTEIN 1BETA; MAMMAGLOBIN B; MAMMALIAN TARGET OF RAPAMYCIN; MATRIX METALLOPROTEINASE; MEMBRANE PROTEIN; PHOSPHATIDYLINOSITOL 4,5 BISPHOSPHATE 3 KINASE; PHOSPHATIDYLINOSITOL 4,5 BISPHOSPHATE 3 KINASE CATALYTIC SUBUNIT ALPHA; RAD51 PROTEIN; TRANSCRIPTION FACTOR ZEB1; TRANSCRIPTOME; UNCLASSIFIED DRUG; VASCULOTROPIN RECEPTOR; VIMENTIN; RNA;

ARTICLE; BREAST CANCER CELL LINE; CANCER GROWTH; CANCER RESISTANCE; CANCER STEM CELL; CELL HETEROGENEITY; CIRCULATING TUMOR CELL; CONTROLLED STUDY; DNA REPAIR; EPITHELIAL MESENCHYMAL TRANSITION; GENE EXPRESSION; GENE EXPRESSION PROFILING; HUMAN; HUMAN CELL; IMMUNOCOMPETENT CELL; LEUKOCYTE; MALE; PROSTATE CANCER CELL LINE; SIGNAL TRANSDUCTION; SINGLE CELL ANALYSIS; TRANSCRIPTOMICS; GENETICS; METABOLISM; PATHOLOGY; TUMOR CELL CULTURE; TUMOR EMBOLISM;

EPITHELIAL-MESENCHYMAL TRANSITION; GENE EXPRESSION PROFILING; HUMANS; NEOPLASTIC CELLS, CIRCULATING; RNA, NEOPLASM; TRANSCRIPTOME; TUMOR CELLS, CULTURED;

EID: 84994156596     PISSN: 00099147     EISSN: 15308561     Source Type: Journal    
DOI: 10.1373/clinchem.2016.260299     Document Type: Article

References (39)

1. Gorges TM, Pantel K. Circulating tumor cells as therapyrelated biomarkers in cancer patients. Cancer Immunol Immunother 2013;62:931-9.
2. Gasch C, Bauernhofer T, Pichler M, Langer-Freitag S, Reeh M, Seifert AM, et al. Heterogeneity of epidermal growth factor receptor status and mutations of KRAS/PIK3CA in circulating tumor cells of patients with colorectal cancer. Clin Chem 2013;59:252-60.
3. Heitzer E, Auer M, Gasch C, Pichler M, Ulz P, Hoffmann EM, et al. Complex tumor genomes inferred from single circulating tumor cells by array-CGH and nextgeneration sequencing. Cancer Res 2013;73:2965-75.
4. Antonarakis ES, Lu C, Wang H, Luber B, Nakazawa M, Roeser JC, et al. Ar-v7 and resistance to enzalutamide and abiraterone in prostate cancer. N Engl J Med 2014; 371:1028-38.
5. Stathopoulou A, Angelopoulou K, Perraki M, Georgoulias V, Malamos N, Lianidou E. Quantitative rt-pcr luminometric hybridization assay with an RNA internal standard for cytokeratin-19 mRNA in peripheral blood of patients with breast cancer. Clin Biochem 2001;34: 651-9.
6. Stathopoulou A, Gizi A, Perraki M, Apostolaki S, Malamos N, Mavroudis D, et al. Real-time quantification of ck-19 mRNA-positive cells in peripheral blood of breast cancer patients using the lightcycler system. Clin Cancer Res 2003;9:5145-51.
7. Kasimir-Bauer S, Hoffmann O, Wallwiener D, Kimmig R, Fehm T. Expression of stem cell and epithelialmesenchymal transition markers in primary breast cancer patients with circulating tumor cells. Breast Cancer Res 2012;14:R15.
8. Vaiopoulos AG, Kostakis ID, Gkioka E, Athanasoula K, Pikoulis E, Papalambros A, et al. Detection of circulating tumor cells in colorectal and gastric cancer using a multiplex PCR assay. Anticancer Res 2014;34:3083-92.
9. Yu M, Bardia A, Wittner BS, Stott SL, Smas ME, Ting DT, et al. Circulating breast tumor cells exhibit dynamic changes in epithelial and mesenchymal composition. Science 2013;339:580-4.
10. Ozkumur E, Shah AM, Ciciliano JC, Emmink BL, Miyamoto DT, Brachtel E, et al. Inertial focusing for tumor antigen-dependent and-independent sorting of rare circulating tumor cells. Sci Transl Med 2013;5: 179ra47.
11. Hvichia GE, Parveen Z, Wagner C, Janning M, Quidde J, Stein A, et al. A novel microfluidic platform for size and deformability based separation and the subsequent molecular characterization of viable circulating tumor cells. Int J Cancer 2016;138:2894-904.
12. Stahlberg A, Rusnakova V, Forootan A, Anderova M, Kubista M. RT-qPCR workflow for single-cell data analysis. Methods 2013;59:80-8.
13. Bengtsson M, Stahlberg A, Rorsman P, Kubista M. Gene expression profiling in single cells from the pancreatic islets of Langerhans reveals lognormal distribution of mrna levels. Genome Res 2005;15:1388-92.
14. Stahlberg A, Hakansson J, Xian X, Semb H, Kubista M. Properties of the reverse transcription reaction in mRNA quantification. Clin Chem 2004;50:509-15.
15. Bergkvist A, Rusnakova V, Sindelka R, Garda JM, Sjogreen B, Lindh D, et al. Gene expression profiling: clusters of possibilities. Methods 2010;50:323-35.
16. Yang P, Guo L, Duan ZJ, Tepper CG, Xue L, Chen X, et al. Histone methyltransferase NSD2/MMSET mediates constitutive NF-kappaB signaling for cancer cell proliferation, survival, and tumor growth via a feed-forward loop. Mol Cell Biol 2012;32:3121-31.
17. Welti J, Loges S, Dimmeler S, Carmeliet P. Recent molecular discoveries in angiogenesis and antiangiogenic therapies in cancer. J Clin Invest 2013;123:3190-200.
18. Anantharaman A, Friedlander TW. Targeting the androgen receptor in metastatic castrate-resistant prostate cancer: a review. Urol Oncol 2016;34:356-67.
19. Zhang L, Altuwaijri S, Deng F, Chen L, Lal P, Bhanot UK, et al. NF-KappaB regulates androgen receptor expression and prostate cancer growth. Am J Pathol 2009; 175:489-99.
20. Bowen C, Zheng T, Gelmann EP. Nkx3.1 suppresses tmprss2-erg gene rearrangement and mediates repair of androgen receptor-induced DNA damage. Cancer Res 2015;75:2686-98.
21. Mitra A, Jameson C, Barbachano Y, Sanchez L, Kote-Jarai Z, Peock S, et al. Overexpression of RAD51 occurs in aggressive prostatic cancer. Histopathology 2009; 55:696-704.
22. Bosch-Barrera J, Menendez JA. Silibinin and STAT3: a natural way of targeting transcription factors for cancer therapy. Cancer Treat Rev 2015;41:540-6.
23. Schreiber RD, Old LJ, Smyth MJ. Cancer immunoediting: integrating immunity's roles in cancer suppression and promotion. Science 2011;331: 1565-70.
24. Mukaida N, Sasaki S, Baba T. Id: 33: CCL4 can promote bone metastasis of a murine breast cancer cell line, by interacting CCR5-expressing non-tumor cells in bone marrow. Cytokine 2015;76:70.
25. Kuniyasu H, Oue N, Nakae D, Tsutsumi M, Denda A, Tsujiuchi T, et al. Interleukin-15 expression is associated with malignant potential in colon cancer cells. Pathobiology 2001;69:86-95.
26. Kumar N, Singh A, Kulkarni RV. Transcriptional bursting in gene expression: analytical results for general stochastic models. PLoS Comput Biol 2015;11: e1004292.
27. Yu M, Stott S, Toner M, Maheswaran S, Haber DA. Circulating tumor cells: approaches to isolation and characterization. J Cell Biol 2011;192:373-82.
28. Alix-Panabieres C, Pantel K. Challenges in circulating tumor cell research. Nat Rev Cancer 2014;14:623-31.
29. Riethdorf S, Muller V, Zhang L, Rau T, Loibl S, Komor M, et al. Detection and HER2 expression of circulating tumor cells: prospective monitoring in breast cancer patients treated in the neoadjuvant GeparQuattro trial. Clin Cancer Res 2010;16:2634-45.
30. Muniyan S, Chen SJ, Lin FF, Wang Z, Mehta PP, Batra SK, Lin MF. Erbb-2 signaling plays a critical role in regulating androgen-sensitive and castration-resistant androgen receptor-positive prostate cancer cells. Cell Signal 2015;27:2261-71.
31. Johnston SR. Enhancing endocrine therapy for hormone receptor-positive advanced breast cancer cotargeting signaling pathways. J Natl Cancer Inst 2015; 107.
32. Nagaraj G, Ma C. Revisiting the estrogen receptor pathway and its role in endocrine therapy for postmenopausal women with estrogen receptor-positive metastatic breast cancer. Breast Cancer Res Treat 2015;150: 231-42.
33. Kristensen TB, Knutsson ML, Wehland M, Laursen BE, Grimm D, Warnke E, Magnusson NE. Antivascular endothelial growth factor therapy in breast cancer. Int J Mol Sci 2014;15:23024-41.
34. Clarke MF, Dick JE, Dirks PB, Eaves CJ, Jamieson CH, Jones DL, et al. Cancer stem cells-perspectives on current status and future directions: AACR Workshop on cancer stem cells. Cancer Res 2006;66:9339-44.
35. Jaggupilli A, Elkord E. Significance of CD44 and CD24 as cancer stem cell markers: an enduring ambiguity. Clin Dev Immunol 2012;2012:708036.
36. Yeung TM, Gandhi SC, Wilding JL, Muschel R, Bodmer WF. Cancer stem cells from colorectal cancer-derived cell lines. Proc Natl Acad Sci USA 2010;107:3722-7.
37. Wu P, Liu T, Hu Y. PI3K inhibitors for cancer therapy: what has been achieved so far? Curr Med Chem 2009; 16:916-30.
38. Baselga J, Campone M, Piccart M, Burris HA, 3rd, Rugo HS, Sahmoud T, et al. Everolimus in postmenopausal hormone-receptor-positive advanced breast cancer. N Engl J Med 2012;366:520-9.
39. Chen J, Weiss WA. Alternative splicing in cancer: implications for biology and therapy. Oncogene 2015;34:1-14.